Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07387354 | Pacritinib With Aza for Upfront Myelodysplastic Syndrome(MDS) | withdrawn | Phase 1 / Phase 2 | 0 | Thomas Jefferson UniversityOTHER | 0 |
| Aug 17, 2026 |
| clinicaltrials |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT06284460 | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06351306 | DEC-C and Thioguanine for R/R AML | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 24, 2025 | clinicaltrials |
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Guenther KoehneOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | withdrawn | Phase 2 | 0 | Northside Hospital, Inc.OTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 11, 2024 | clinicaltrials |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | withdrawn | Phase 2 | 0 | Uwe PlatzbeckerOTHER | 0 | Feb 12, 2024 | clinicaltrials |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04629651 | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | withdrawn | Phase 1 / Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 1, 2023 | clinicaltrials |
| NCT00816413 | Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | withdrawn | Phase 1 / Phase 2 | 0 | Actinium PharmaceuticalsINDUSTRY | 0 | Jul 20, 2023 | clinicaltrials |
| NCT03745352 | Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 27, 2023 | clinicaltrials |
| NCT04354025 | Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Apr 4, 2023 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | withdrawn | Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04354727 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies(HERKULES-4) | withdrawn | Phase 1 / Phase 2 | 0 | Erasca, Inc.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04893915 | Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT04044209 | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04395092 | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | withdrawn | Phase 2 | 0 | Kiadis PharmaINDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03881735 | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02973711 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03515707 | Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS | withdrawn | Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Jul 31, 2020 | clinicaltrials |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jul 7, 2020 | clinicaltrials |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Path Holdings, Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia(CyFi2) | withdrawn | Phase 2 | 0 | AVEO Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 31, 2020 | clinicaltrials |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia | withdrawn | Phase 2 | 0 | Matinas BioPharma Nanotechnologies, Inc.INDUSTRY | 0 | Mar 8, 2019 | clinicaltrials |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT03365661 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 1 | Oct 22, 2018 | clinicaltrials |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 2, 2018 | clinicaltrials |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 21, 2018 | clinicaltrials |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 4, 2018 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials